AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
18.8 C
New York
Tuesday, September 8, 2026

Tag: medications

ARMR Sciences Achieves Major Milestone Toward Overdose Protection, Produces First-Ever Anti-Fentanyl Immune Response in Humans

Interim phase 1/2 data confirm significant anti-fentanyl antibody production at the lowest dose, with a well-tolerated safety profile across all patients dosed. NEW YORK,...

Boston Business Journal names Interra Health to 2026 Best Places to Work List

The Boston Business Journal has named Interra Health to its 2026 Best Places to Work list.

Rivox Labs Launches Nicotine-Free Focus Pouches and Energy Gum

A new focus brand out of Austin is here to kill your brain fog without selling you a habit. Pre-orders open now.
A new focus brand out of Austin is here to kill your brain fog without selling you a habit. Pre-orders open now.

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

UK’s leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides

LONDON, June 12, 2026 /PRNewswire/ -- Get A Drip, one of the UK's largest providers of longevity health treatments, is strengthening its clinical leadership...

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.

AEROFARMS ACQUIRED BY AN AFFILIATE OF PALM VENTURES, POSITIONS U.S. MICROGREENS LEADER FOR EXPANDED DISTRIBUTION AND LONG-TERM GROWTH

Mission-aligned ownership and new leadership will increase access to sustainably grown microgreensDANVILLE, Va., June 11, 2026 /PRNewswire/ -- AeroFarms, an indoor vertical farming company and...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedications